CHST7

Across TCGA pan-cancer cohorts, CHST7 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CHST7 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CHST7 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CHST7 expression acts as an unfavorable survival marker, although some lineages such as GBM and LUAD show a favorable association.

LSCC, GBM, and LUAD are the cancer types where CHST7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	All	0.824	0.978	.016	4	view →
GBM	OS	Median	All	0.578	0.284	.002	4	view →
LUAD	DFS	Median	All	1.000	0.781	.010	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CHST7–LSCC (OS)

Open the LSCC breakdown →